Regulation of intrapleural fibrinolysis by urokinase-α-macroglobulin complexes in tetracycline-induced pleural injury in rabbits

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 297, Issue 4, 2009, Pages

  Komissarov, Andrey A ^a   Mazar, Andrew P ^b   Koenig, Kathy ^a   Kurdowska, Anna K ^a   Idell, Steven ^a  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

^b Attenuon Limited Liability Company   (United States)

Author keywords

Single chain urokinase; Tissue plasminogen activator

Indexed keywords

ALANINE; ALPHA 2 MACROGLOBULIN; ALTEPLASE; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERINE; TETRACYCLINE; UROKINASE; UROKINASE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG MEGADOSE; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FIBRINOLYSIS; IMMUNOPRECIPITATION; LOW DRUG DOSE; LUNG INJURY; NONHUMAN; PLEURA; PLEURA FLUID; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RABBIT; REGULATORY MECHANISM;

ALPHA-MACROGLOBULINS; ANIMALS; BLOTTING, WESTERN; FEMALE; FIBRINOLYSIS; IMMUNOPRECIPITATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLEURA; PROTEIN SYNTHESIS INHIBITORS; RABBITS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RECOMBINANT PROTEINS; TETRACYCLINE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 70349764561     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00066.2009     Document Type: Article

References (41)

1. Banbula A, Chang LS, Beyer WF, Bohra CL, Cianciolo GJ, Pizzo SV. The properties of rabbit alpha1-macroglobulin upon activation are distinct from those of rabbit and human alpha2-macroglobulins. J Biochem 138: 527-537, 2005. (Pubitemid 43058222)
2. Barrett AJ, Starkey PM. The interaction of alpha 2-macroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism. Biochem J 133: 709-724, 1973.
3. Behrendt N, List K, Andreasen PA, Dano K. The pro-urokinase plasminogen- activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation. Biochem J 371: 277-287, 2003. (Pubitemid 36547610)
4. Bode W. The transition of bovine trypsinogen to a trypsin-like state upon strong ligand binding. II. The binding of the pancreatic trypsin inhibitor and of isoleucine-valine and of sequentially related peptides to trypsinogen and to p-guanidinobenzoate-trypsinogen. J Mol Biol 127: 357-374, 1979.
5. Boose JA, Kuismanen E, Gerard R, Sambrook J, Gething MJ. The single-chain form of tissue-type plasminogen activator has catalytic activity: studies with a mutant enzyme that lacks the cleavage site. Biochemistry 28: 635-643, 1989. (Pubitemid 19047101)
6. Borth W. Alpha 2-macroglobulin, a multifunctional binding protein with targeting characteristics. FASEB J 6: 3345-3353, 1992. (Pubitemid 23007099)
7. Bouros D, Schiza S, Tzanakis N, Drositis J, Siafakas N. Intrapleural urokinase in the treatment of complicated parapneumonic pleural effusions and empyema. Eur Respir J 9: 1656-1659, 1996. (Pubitemid 26271150)
8. Cameron R, Davies HR. Intra-pleural fibrinolytic therapy versus conservative management in the treatment of adult parapneumonic effusions and empyema. Cochrane Database Syst Rev CD002312, 2008. (Pubitemid 351807349)
9. Davies RJ, Traill ZC, Gleeson FV. Randomised controlled trial of intrapleural streptokinase in community acquired pleural infection. Thorax 52: 416-421, 1997.
10. Harada S, Dannenberg AM Jr, Vogt RF Jr, Myrick JE, Tanaka F, Redding LC, Merkhofer RM, Pula PJ, Scott AL. Inflammatory mediators and modulators released in organ culture from rabbit skin lesions produced in vivo by sulfur mustard. III. Electrophoretic protein fractions, trypsin-inhibitory capacity, alpha 1-proteinase inhibitor, and alpha 1-and alpha 2-macroglobulin proteinase inhibitors of culture fluids and serum. Am J Pathol 126: 148-163, 1987. (Pubitemid 17007961)
11. Harpel PC, Mosesson MW. Degradation of human fibrinogen by plasms alpha2-macroglobulin-enzyme complexes. J Clin Invest 52: 2175-2184, 1973.
12. Higazi AA, Mazar A, Wang J, Reilly R, Henkin J, Kniss D, Cines D. Single-chain urokinase-type plasminogen activator bound to its receptor is relatively resistant to plasminogen activator inhibitor type 1. Blood 87: 3545-3549, 1996. (Pubitemid 26129580)
13. Hinata A, Iijima M, Nakano Y, Sakamoto T, Tomita M. Chemical characterization of rabbit alpha 2-macroglobulin. Chem Pharm Bull (Tokyo) 35: 271-276, 1987.
14. Idell S. Update on the Use of Fibrinolysins in Pleural Disease. Clinical Pulmonary Medicine 12: 184-190, 2005. (Pubitemid 40686611)
15. Idell S, Allen T, Chen S, Koenig K, Mazar A, Azghani A. Intrapleural activation, processing, efficacy, and duration of protection of single-chain urokinase in evolving tetracycline-induced pleural injury in rabbits. Am J Physiol Lung Cell Mol Physiol 292: L25-L32, 2007. (Pubitemid 46103427)
16. Idell S, Azghani A, Chen S, Koenig K, Mazar A, Kodandapani L, Bdeir K, Cines D, Kulikovskaya I, Allen T. Intrapleural low-molecular- weight urokinase or tissue plasminogen activator versus single-chain urokinase in tetracycline-induced pleural loculation in rabbits. Exp Lung Res 33: 419-440, 2007. (Pubitemid 350125562)
17. Idell S, Girard W, Koenig KB, McLarty J, Fair DS. Abnormalities of pathways of fibrin turnover in the human pleural space. Am Rev Respir Dis 144: 187-194, 1991.
18. Idell S, Mazar A, Cines D, Kuo A, Parry G, Gawlak S, Juarez J, Koenig K, Azghani A, Hadden W, McLarty J, Miller E. Single-chain urokinase alone or complexed to its receptor in tetracycline-induced pleuritis in rabbits. Am J Respir Crit Care Med 166: 920-926, 2002. (Pubitemid 35193219)
19. Komissarov AA, Declerck PJ, Shore JD. Mechanisms of conversion of plasminogen activator inhibitor 1 from a suicide inhibitor to a substrate by monoclonal antibodies. J Biol Chem 277: 43858-43865, 2002.
20. Kvassman JO, Shore JD. Purification of human plasminogen activator inhibitor (PAI-1) from Escherichia coli and separation of its active and latent forms by hydrophobic interaction chromatography. Fibrinolysis 9: 215-221, 1995.
21. Light RW. Parapneumonic effusions and empyema. Proc Am Thorac Soc 3: 75-80, 2006.
22. Lijnen HR, Van HB, Nelles L, Collen D. Plasminogen activation with single-chain urokinase-type plasminogen activator (scu-PA). Studies with active site mutagenized plasminogen (Ser740-Ala) and plasmin-resistant scu-PA (Lys158-Glu). J Biol Chem 265: 5232-5236, 1990. (Pubitemid 20117178)
23. Manchanda N, Schwartz BS. Interaction of single-chain urokinase and plasminogen activator inhibitor type 1. J Biol Chem 270: 20032-20035, 1995.
24. Maskell NA, Davies CW, Nunn AJ, Hedley EL, Gleeson FV, Miller R, Gabe R, Rees GL, Peto TE, Woodhead MA, Lane DJ, Darbyshire JH, Davies RJ. U.K. controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med 352: 865-874, 2005. (Pubitemid 40300295)
25. Murano G, Aronson D, Williams L, Brown L. The inhibition of high and low molecular weight urokinase in plasma. Blood 55: 430-436, 1980. (Pubitemid 10148264)
26. Nienaber VL, Young SL, Birktoft JJ, Higgins DL, Berliner LJ. Conformational similarities between one-chain and two-chain tissue plasminogen activator (t-PA): implications to the activation mechanism on one-chain t-PA. Biochemistry 31: 3852-3861, 1992.
27. Ogston D, Bennett B, Herbert RJ, Douglas AS. The inhibition of urokinase by alpha 2-macroglobulin. Clin Sci 44: 73-79, 1973.
28. Pannell R, Gurewich V. Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect. Blood 67: 1215-1223, 1986. (Pubitemid 16080585)
29. Philip-Joet F, Alessi MC, Philip-Joet C, Aillaud M, Barriere JR, Arnaud A, Juhan-Vague I. Fibrinolytic and inflammatory processes in pleural effusions. Eur Respir J 8: 1352-1356, 1995.
30. Ranby M, Bergsdorf N, Nilsson T. Enzymatic properties of the one- and two-chain form of tissue plasminogen activator. Thromb Res 27: 175-183, 1982. (Pubitemid 12019056)
31. Renatus M, Engh RA, Stubbs MT, Huber R, Fischer S, Kohnert U, Bode W. Lysine 156 promotes the anomalous proenzyme activity of tPA: X-ray crystal structure of single-chain human tPA. EMBO J 16: 4797-4805, 1997. (Pubitemid 27348389)
32. Sahn SA. Use of fibrinolytic agents in the management of complicated parapneumonic effusions and empyemas. Thorax 53, Suppl 2: S65-S72, 1998.
33. Salvesen GS, Barrett AJ. Covalent binding of proteinases in their reaction with alpha 2-macroglobulin. Biochem J 187: 695-701, 1980.
34. Shore JD, Day DE, Francis-Chmura AM, Verhamme I, Kvassman J, Lawrence DA, Ginsburg D. A fluorescent probe study of plasminogen activator inhibitor-1. Evidence for reactive center loop insertion and its role in the inhibitory mechanism. J Biol Chem 270: 5395-5398, 1995.
35. Sonnappa S, Cohen G, Owens CM, van Doorn C, Cairns J, Stanojevic S, Elliott MJ, Jaffe A. Comparison of urokinase and video-assisted thoracoscopic surgery for treatment of childhood empyema. Am J Respir Crit Care Med 174: 221-227, 2006. (Pubitemid 44015396)
36. Sottrup-Jensen L. Alpha-macroglobulins: structure, shape, and mechanism of proteinase complex formation. J Biol Chem 264: 11539-11542, 1989. (Pubitemid 19185316)
37. Straight DL, Hassett MA, McKee PA. Structural and functional characterization of the inhibition of urokinase by alpha 2-macroglobulin. Biochemistry 24: 3902-3907, 1985.
38. Tamamizu S, Miyake Y, Ito T, Sinohara H. Changes in trypsin-binding properties and conformation of rabbit alpha-2-macroglobulin on reaction with methylamine. J Biochem 105: 898-904, 1989. (Pubitemid 19147417)
39. Tillett WS, Sherry S. The effect in patients of streptococcal fibrinolysin (streptokinase) and streptococcal desoxyribonuclease on fibrinous, purulent and sanguinous pleural exudations. J Clin Invest 28: 173-190, 1949.
40. Tillett WS, Sherry S, Read CT. The use of streptokinase-streptodornase in the treatment of postpneumonic empyema. J Thorac Surg 21: 275-297, 1951.
41. Waller EK, Schleuning WD, Reich E. Complex-formation and inhibition of urokinase by blood plasma proteins. Biochem J 215: 123-131, 1983.